Dr O’Neil explains how early patient engagement and honest feedback shaped tailored treatments in cystic fibrosis, namely our Lynovex therapies (oral and inhaled).
The full article can be accessed here Rare Revolution Article
Patients at the centre of rare disease therapy development
Dr Deborah O’Neil, CEO of NovaBiotics, features in the latest issue of Rare Revolution Magazine in the Patient Partners edition.